GlassScriptPhysician profile
Prithviraj Dharmaraja
NPI 1932111424
$8,039.02
in general payments reported to CMS, 2019-2025
32 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948 · 2020: $232 · 2021: $1,433 · 2022: $967 · 2023: $1,557 · 2024: $1,736 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,449 · Education: $9.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,449.30 |
| Education | $9.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,310.86 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $687.74 | 2019-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $628.23 | 2019-2025 | Epclusa |
| Janssen Biotech, INC. | $571.14 | 2020-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $392.23 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $340.86 | 2019-2024 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $288.49 | 2024-2025 | Voquezna |
| Pfizer INC. | $239.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $238.42 | 2019-2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.90 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $223.45 | 2022-2024 | Dupixent |
| Genzyme Corporation | $193.93 | 2022-2024 | |
| Madrigal Pharmaceuticals | $181.08 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $140.18 | 2019 | |
| Tempus Ai, INC | $140.17 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $134.64 | 2021-2023 | |
| Ardelyx, INC. | $127.56 | 2022-2023 | Ibsrela |
| Lilly USA, LLC | $125.00 | 2025 | Jardiance |
| Optinose US, INC. | $124.99 | 2021 | |
| Braintree Laboratories, INC. | $112.74 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $103.80 | 2020-2024 | |
| Dova Pharmaceuticals | $96.94 | 2019 | |
| Evoke Pharma, INC. | $83.46 | 2021-2023 | Gimoti |
| Endogastric Solutions, INC | $75.04 | 2019 | |
| Intercept Pharmaceuticals, INC. | $74.89 | 2020-2024 | Ocaliva |
| Celgene Corporation | $48.36 | 2021-2023 | Zeposia |
| Capsovision, INC. | $34.43 | 2024-2025 | Capsocam Plus |
| Alcresta Therapeutics, INC. | $22.33 | 2023 | Relizorb |
| Shionogi INC | $17.15 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $14.77 | 2025 | Riteclip |
| Allergan, INC. | $14.64 | 2019 | |
| Alfasigma USA, INC. | $14.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prithviraj Dharmaraja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.